The estimated Net Worth of Ilya Yuffa is at least $15.8 Milione dollars as of 1 February 2024. Mr. Yuffa owns over 3,702 units of Lilly(Eli) & Co stock worth over $15,356,762 and over the last 4 years he sold LLY stock worth over $480,040. In addition, he makes $0 as Senior Vice President and President of Lilly Bio-Medicines at Lilly(Eli) & Co.
Sign up
Mr. Yuffa LLY stock SEC Form 4 insiders trading
Ilya has made over 2 trades of the Lilly(Eli) & Co stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,702 units of LLY stock worth $3,409,135 on 1 February 2024.
The largest trade he's ever made was exercising 3,702 units of Lilly(Eli) & Co stock on 1 February 2024 worth over $3,409,135. On average, Ilya trades about 950 units every 119 days since 2021. As of 1 February 2024 he still owns at least 16,676 units of Lilly(Eli) & Co stock.
You can see the complete history of Mr. Yuffa stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ilya Yuffa biography
Ilya Yuffa has been appointed as Senior Vice President and President of Lilly Bio-Medicines of the Company effective 10/1/2020. Early in his 25-year Lilly career, Yuffa held roles in finance and business development, and earned his MBA from the London Business School . He later served in sales and general leadership roles across the enterprise and held senior level positions in the company's six sigma and ethics and compliance organizations. Before assuming leadership for U.S. Diabetes in 2018, Yuffa served as general manager of Italy .
What's Ilya Yuffa's mailing address?
Ilya's mailing address filed with the SEC is Eli Lilly and Company Corporate Center, Indianapolis, Marion County, Indiana, United States.
Insiders trading at Lilly(Eli) & Co
Over the last 20 years, insiders at Lilly(Eli) & Co have traded over $29,994,829,903 worth of Lilly(Eli) & Co stock and bought 73,808 units worth $5,778,435 . The most active insiders traders include Endowment Inc Lilly, R David Hoover e Lorenzo Tallarigo. On average, Lilly(Eli) & Co executives and independent directors trade stock every 7 days with the average trade being worth of $55,447,708. The most recent stock trade was executed by Endowment Inc Lilly on 3 September 2024, trading 24,084 units of LLY stock currently worth $23,281,762.
What does Lilly(Eli) & Co do?
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.
What does Lilly(Eli) & Co's logo look like?
Complete history of Mr. Yuffa stock trades at Lilly(Eli) & Co
Lilly(Eli) & Co executives and stock owners
Lilly(Eli) & Co executives and other stock owners filed with the SEC include:
-
David Ricks,
Chairman of the Board, President, Chief Executive Officer -
Joshua Smiley,
Chief Financial Officer, Senior Vice President -
Daniel Skovronsky,
Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories -
David A. Ricks,
Chairman, CEO & Pres -
Anat Hakim J.D.,
Sr. VP, Gen. Counsel & Sec. -
Jackson Tai,
Independent Director -
Juan Luciano,
Lead Independent Director -
J. Erik Fyrwald,
Independent Director -
Karen Walker,
Independent Director -
William Kaelin,
Independent Director -
Michael Eskew,
Independent Director -
Jamere Jackson,
Independent Director -
Katherine Baicker,
Independent Director -
Raul Alvarez,
Independent Director -
Kathi Seifert,
Independent Director -
Marschall Runge,
Independent Director -
Carolyn Bertozzi,
Independent Director -
Alfonso Zulueta,
Senior Vice President, President - Lilly International -
Ilya Yuffa,
Senior Vice President and President of Lilly Bio-Medicines -
Anne White,
Senior Vice President, President - Lilly Oncology -
Leigh Pusey,
Senior Vice President - Corporate Affairs and Communications -
Myles O'Neill,
Senior Vice President and President - Manufacturing Operations -
Johna Norton,
Senior Vice President - Global Quality -
Michael Mason,
Senior Vice President and President, Lilly Diabetes -
Patrik Jonsson,
Senior Vice President, President of Lilly USA , and Chief Customer Officer -
Stephen Fry,
Senior Vice President - Human Resources and Diversity -
Anat Hakim,
Senior Vice President, General Counsel -
Melissa Barnes,
Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer -
Aarti Shah,
Senior Vice President - Chief Information and Digital Officer -
Leigh Ann Pusey,
Sr. VP of Corp. Affairs & Communications -
Alonzo Weems,
Sr. VP and Chief Ethics & Compliance Officer -
Diogo Rau,
Sr. VP & Chief Information and Digital Officer -
Kevin Hern,
VP of Investor Relations -
Martin Bott MIBS,
VP of Fin. & Special Projects -
Donald A. Zakrowski,
Chief Accounting Officer & VP of Fin. -
Jacob S. Van Naarden,
Chief Operating Officer of Loxo Oncology -
Anat Ashkenazi,
Sr. VP & CFO -
Eric Dozier,
EVP, HR & Diversity -
Endowment Inc Lilly,
-
Christi Shaw,
SVP and Pres., Lilly Bio-Meds -
Fionnuala M Walsh,
SVP, Global Quality -
Jan M Lundberg,
EVP,Science&Tech and Pres. LRL -
Maria A Crowe,
President, Mfg. Operations -
Ralph Alvarez,
Director -
Michael J Harrington,
Senior VP and General Counsel -
Jeffrey N Simmons,
SVP&Pres.,Elanco Animal Health -
Susan Mahony,
SVP, HR & Diversity -
Barton R Peterson,
Sr. VP, Corp. Affairs & Comm. -
Derica W Rice,
Sr. Vice President and CFO -
Enrique A Conterno,
Sr. VP & Pres., Lilly Diabetes -
Naarden Jacob Van,
EVP & Pres., Loxo@Lilly -
Donald A Zakrowski,
SVP, Finance, & CAO -
Karen N Horn,
Director -
John C Lechleiter,
President and COO -
Alonzo Weems,
EVP, ERM & CECO -
R David Hoover,
Director -
Franklyn G Prendergast,
Director -
Ellen R Marram,
Director -
Douglas R Oberhelman,
Director -
Anne Nobles,
Chief Eth/Cmpl Ofcr & SVP, ERM -
Bryce D. Carmine,
EVP and Pres, Lilly Bio-Meds -
Robert A Armitage,
Sr. VP and General Counsel -
Steven M Paul,
EVP, Science and Technology -
Frank M Deane,
President, Manufacturing -
J Michael Cook,
Director -
Alfred G Gilman,
Director -
Martin S Feldstein,
Director -
Sidney Taurel,
Chairman, President and CEO -
Alex M Ii Azar,
Sr. VP, Corp. Affairs & Comm. -
Gino Santini,
Sr.VP, Corp. Strategy & Policy -
Deirdre P Connelly,
President, Lilly USA -
Anthony John Murphy,
Senior VP, Human Resources -
Jacques Tapiero,
SVP&Pres., Emerging Markets -
Winfried F W Sir Bischoff,
Director -
Arnold C Hanish,
Chief Accounting Officer -
Lorenzo Tallarigo,
President, Internat'l Opers. -
George M C Fisher,
Director -
Scott A Canute,
President, Mfg. Operations -
Charles E Golden,
Exec. Vice President and CFO -
Kimberly H Johnson,
Director -
Anat Ashkenazi,
EVP & CFO -
Diogo Rau,
EVP & CIDO -
Edgardo Hernandez,
EVP & Pres., Mfg. Operations -
Gabrielle Sulzberger,
Director -
Mary Lynne Hedley,
Director -
Melissa Seymour,
EVP, Global Quality